NanoViricides, Inc. the Company , is a nano biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life threatening viral infections. We are a development stage company with several drugs in various stages of early development.
Quote | NanoViricides Inc. (NYSE:NNVC)
Last: | $1.10 |
---|---|
Change Percent: | -1.28% |
Open: | $1.19 |
Close: | $1.10 |
High: | $1.19 |
Low: | $1.09 |
Volume: | 22,323 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | NanoViricides Inc. (NYSE:NNVC)
2024-02-15 06:38:29 ET More on NanoViricides Seeking Alpha’s Quant Rating on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides Read the full article on Seeking Alpha For further details see: Na...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...
Message Board Posts | NanoViricides Inc. (NYSE:NNVC)
Subject | By | Source | When |
---|---|---|---|
Companys Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness | drkazmd65 | investorshub | 07/11/2023 2:43:07 PM |
We're up almost to $1.60 (it was briefly | drkazmd65 | investorshub | 07/11/2023 2:36:58 PM |
Thanks for the thoughts. | loanranger | investorshub | 07/10/2023 9:33:09 PM |
It's impossible to know the exact details of | KMBJN | investorshub | 07/10/2023 4:37:50 PM |
what does this mean? | arvitar | investorshub | 07/10/2023 11:56:22 AM |
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 o...
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial...